DrugPatentWatch Database Preview
ZEGALOGUE Drug Patent Profile
Email this page to a colleague
When do Zegalogue patents expire, and when can generic versions of Zegalogue launch?
Zegalogue is a drug marketed by Zealand Pharma and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-one patent family members in twenty-three countries.
The generic ingredient in ZEGALOGUE is dasiglucagon hydrochloride. Additional details are available on the dasiglucagon hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Zegalogue
Zegalogue will be eligible for patent challenges on March 22, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 3, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for ZEGALOGUE
| International Patents: | 31 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in ZEGALOGUE? | ZEGALOGUE excipients list |
| DailyMed Link: | ZEGALOGUE at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ZEGALOGUE
Generic Entry Date for ZEGALOGUE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for ZEGALOGUE
US Patents and Regulatory Information for ZEGALOGUE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zealand Pharma | ZEGALOGUE | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-001 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Zealand Pharma | ZEGALOGUE | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-001 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Zealand Pharma | ZEGALOGUE (AUTOINJECTOR) | dasiglucagon hydrochloride | SOLUTION;SUBCUTANEOUS | 214231-002 | Mar 22, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZEGALOGUE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 704043 | ⤷ Try it Free |
| Japan | 2019187419 | ⤷ Try it Free |
| European Patent Office | 2875043 | ⤷ Try it Free |
| Denmark | 2875043 | ⤷ Try it Free |
| Eurasian Patent Organization | 033399 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
